Eli Lilly's financial reports or public financial disclosures

FDA Approves Eli Lilly's Zepbound (tirzepatide) as First and Only Treatment for Obstructive Sleep Apnea in Adults with Obesity

Dec 20, 2024, 09:34 PM

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound® (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval marks Zepbound as the first and only prescription medication specifically indicated for this condition in this patient population. The approval was confirmed by multiple sources, highlighting its significance in addressing sleep apnea associated with obesity.